Related Experiment Videos

Inhibition of Suicidal Erythrocyte Death by Volasertib

Abdulla Al Mamun Bhuyan1, A K M Ashiqul Haque2, Itishri Sahu1

  • 1Department of Internal Medicine III, Eberhard-Karls-University of Tuebingen, Tuebingen, Germany.

Abstract

Insights

Volasertib, a cancer drug, inhibits suicidal death (eryptosis) in red blood cells induced by energy depletion and osmotic shock. However, it does not affect eryptosis triggered by oxidative stress or calcium influx.

Area of Science:

  • Hematology
  • Cell Biology
  • Pharmacology

Background:

  • Polo-like kinase 1 (Plk1) inhibitor volasertib treats malignancy by inducing tumor cell apoptosis.
  • Eryptosis, or suicidal red blood cell death, shares features with apoptosis, including phosphatidylserine exposure and cell shrinkage.
  • Eryptosis can be triggered by energy depletion, hyperosmotic shock, oxidative stress, and increased intracellular calcium.

Purpose of the Study:

  • To investigate the impact of volasertib on eryptosis in human erythrocytes.
  • To compare volasertib's effects on red blood cell eryptosis with its effects on cancer cell apoptosis.

Main Methods:

  • Human erythrocytes were subjected to eryptosis-inducing conditions (energy depletion, hyperosmotic shock, oxidative stress, ionomycin) with or without volasertib.
  • Flow cytometry was used to quantify phosphatidylserine exposure, cell volume, intracellular calcium, reactive oxygen species, and ceramide.
  • Human leukemic K562 cells were also treated with volasertib for comparison.

Main Results:

  • Volasertib alone did not affect erythrocyte phosphatidylserine exposure or cell volume.
  • Volasertib significantly reduced phosphatidylserine exposure caused by energy depletion and hyperosmotic shock.
  • Volasertib did not alter volasertib-induced phosphatidylserine exposure from oxidative stress or ionomycin, nor did it affect cell volume changes.

Conclusions:

  • Volasertib acts as a novel inhibitor of red blood cell membrane scrambling during eryptosis induced by energy depletion and hyperosmotic shock.
  • These findings contrast with volasertib's known effect of stimulating apoptosis in K562 cancer cells.

Related Concept Videos